TM-2-51
Based on 1 Customer Validation
TM-2-51 is a HDAC8 activator with a Kd value of 0.28 μM. TM-2-51 inhibits α-glucosidase with an IC50 of 171.21 μM. TM-2-51 upregulates HDAC8 expression, modulates the TP53, STAT3/ERK and PI3K-AKT pathways, alleviates LeTx-induced cell cycle arrest, downregulates JMJD3 and increases H3K27me3 levels. TM-2-51 selectively induces apoptosis in tumor cell and upregulates p53/p21 expression. TM-2-51 inhibits tumor cell proliferation, migration and invasion, induces G1-phase arrest and suppresses tumor growth in vivo. TM-2-51 can be used in research on osteosarcoma, anthrax, type 2 diabetes and neuroblastoma.
For research use only. We do not sell to patients.
- Purity : 99.84%
- CAS No.: 4921-82-8
- Formula: C14H12N2OS
- Molecular Weight:256.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
|
HDAC8 0.28 μM (Kd) |
α-Glucosidase 171.21 μM (IC50) |
In Vitro
TM-2-51 (72 h) potently reduces the viability of U2OS and 143B osteosarcoma cells in a concentration-dependent manner[1].
TM-2-51 (6 days) significantly inhibits the colony-forming ability of U2OS and 143B osteosarcoma cells[1].
TM-2-51 (24 h) significantly reduces the proliferation rate of U2OS and 143B osteosarcoma cells[1].
TM-2-51 (24 h) potently inhibits the migration and invasion abilities of U2OS and 143B osteosarcoma cells[1].
TM-2-51 increases the expression levels of HDAC8 and TP53 proteins above the DMSO baseline in U2OS and 143B osteosarcoma cells, while reduces the expression levels of p-STAT3 and p-ERK proteins below the DMSO baseline, without altering the expression levels of total STAT3 and ERK[1].
TM-2-51 (13-50 μM; 48-96 h) protects the human monocytic cell line THP-1 cells against LeTx-induced cytotoxicity, with its cytoprotective effect peaking at 25 μM and enabling continuous cell proliferation within 96 h[2].
TM-2-51 (25 μM; 24-72 h) enhances the phosphorylation level of AKT at Ser-473 in LeTx-treated human monocytic THP-1 cells at a concentration of 25 μM[2].
TM-2-51 (25 μM) increases the level of histone H3K27 trimethylation in LeTx-treated human monocytic THP-1 cells[2].
TM-2-51 (10-80 μM; 24-72 h) selectively inhibits the proliferation of human neuroblastoma SH-SY5Y cells: at a concentration of 80 μM for 72 h, the proliferation inhibition rate is approximately 22%, while it exerts no effect on human neuroblastoma BE (2)-C cells[4].
TM-2-51 (80 μM; 48 h) enhances the expression of p53 and p21 proteins in SH-SY5Y human neuroblastoma cells when treated at a concentration of 80 μM for 48 h, but exerts no effect on the expression of p53 and p21 in BE (2)-C human neuroblastoma cells[4].
TM-2-51 (48 h) increases the proportion of U2OS and 143B osteosarcoma cells in the G1 phase of the cell cycle and induces cell cycle arrest[1].
TM-2-51 (25 μM; 48-72 h) inhibits LeTx-induced G0-G1 cell cycle arrest in the human monocytic cell line THP-1, and restores the cell cycle to a near-normal progression at 72 h[2].
TM-2-51 potently inhibits α-glucosidase with an IC50 of 171.21 μM[3].
TM-2-51 exhibits no cytotoxicity against 3T3 mouse fibroblasts[3].
TM-2-51 (2-20 μM) activates purified recombinant human HDAC8 by decreasing the Michaelis constant (Km, from 650 μM to 184 μM) and increasing the catalytic constant (kcat, from 0.0072 s-1 to 0.035 s-1; all these changes are measured at the highest tested concentration of 20 μM)[4].
TM-2-51 activates purified recombinant human HDAC8 with positive cooperativity; at subsaturating substrate concentrations, its apparent activation constant is 6.1 μM and Hill coefficient is 1.7, whereas cooperativity decreases at saturating substrate concentrations[4].
TM-2-51 (up to 1.8 μM) binds to purified recombinant human HDAC8, with an equilibrium dissociation constant of 0.28 μM and a stoichiometric ratio close to 1:1[4].
TM-2-51 binds to two functional sites on purified recombinant human HDAC8, with negative cooperativity during the binding process; it exhibits the strongest binding affinity at the first site, with a binding constant of 2.09 × 106 M-1[4].
TM-2-51 (100 μM) increases the binding affinity of SAHA to purified recombinant human HDAC8 by approximately 2-fold, and alters the enthalpic and entropic contributions to the binding process[4].
TM-2-51 (80 μM; 72 h) induces approximately 45% apoptosis in human neuroblastoma SH-SY5Y cells when treated at 80 μM for 72 h, but exerts no effect on human neuroblastoma BE (2)-C cells[4].
TM-2-51 (10-48 μM; saturating concentration) potently and selectively activates recombinant human HDAC-8, reaching a maximum activation fold of 26.8 at saturating concentrations (apparent Ka = 12.4 μM), with no activating effect on other tested human HDAC isozymes[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocytic THP-1 cells
-
Concentration:6, 13, 25 and 50 μM
-
Incubation Time:24, 48, 72 and 96 h
-
Result:Exerted a cytoprotective effect against LeTx-induced cytotoxicity, with significant effects starting at 13 μM and maximal effects at 25 μM.
Allowed continuous increases in live cell numbers over 96 h in cells treated with both LeTx and 25 μM TM-2-51, albeit at a slower rate than non-treated cells.
-
Cell Line:human monocytic THP-1 cells
-
Concentration:25 μM
-
Incubation Time:48 h and 72 h
-
Result:Reduced G0-G1 phase distribution to 62.0% at 48 h post-LeTx treatment, compared to 99.5% G0-G1 arrest in LeTx-only cells.
Resulted in near-normal cell cycle distribution (37.6% G0-G1, 8.2% G2-M, 54.2% S phase) at 72 h post-LeTx treatment, compared to LeTx-only cells with 30.8% G0-G1, 1.11% G2-M, and 68.2% S phase.
-
Cell Line:human monocytic THP-1 cells
-
Concentration:25 μM
-
Incubation Time:24 h, 48 h and 72 h
-
Result:Enhanced LeTx-induced AKT phosphorylation at Ser-473 significantly at 24 h, 48 h, and 72 h post-LeTx treatment.
Showed the highest AKT phosphorylation at Ser-473 detected at 72 h post-LeTx treatment.
-
Cell Line:SH-SY5Y human neuroblastoma cells, BE(2)-C human neuroblastoma cells
-
Concentration:0, 10, 40 and 80 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Induced concentration- and time-dependent growth inhibition in SH-SY5Y cells.
Decreased SH-SY5Y cell proliferation by approximately 22% at 80 μM for 72 hours compared to control.
Exerted no growth inhibition effect on BE(2)-C cells under the same conditions.
-
Cell Line:SH-SY5Y human neuroblastoma cells, BE(2)-C human neuroblastoma cells
-
Concentration:80 μM
-
Incubation Time:72 h
-
Result:Induced approximately 45% apoptosis in SH-SY5Y cells compared to DMSO-treated control cells.
Exerted no apoptotic effect on BE(2)-C cells under the same conditions.
-
Cell Line:SH-SY5Y human neuroblastoma cells, BE(2)-C human neuroblastoma cells
-
Concentration:80 μM
-
Incubation Time:48 h
-
Result:Moderately enhanced p53 protein expression in SH-SY5Y cells compared to DMSO-treated controls.
Noticeably enhanced p21 protein expression in SH-SY5Y cells compared to DMSO-treated controls.
Exerted no changes in p53 or p21 expression in BE(2)-C cells under the same conditions.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 2 days; 14 days
-
Result:Reduced tumor weight and tumor volume compared to vehicle control.
Suppressed tumor cell proliferation confirmed by Ki67 staining, with statistically significant differences (***P<0.001).
Chemical Information
-
CAS No. 4921-82-8
-
Appearance Solid
-
Molecular Weight 256.32
-
Formula C14H12N2OS
-
Color White to off-white
-
SMILES
O=C(NC(=S)NC=1C=CC=CC1)C=2C=CC=CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (390.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (762 KB)
- English - EN (762 KB)
- Français - FR (762 KB)
- Deutsch - DE (762 KB)
- Norwegian - NO (762 KB)
- Español - ES (762 KB)
- Swedish - SV (762 KB)
- Italian - IT (762 KB)
- Korean - KR (762 KB)
- Portuguese - PT (762 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang L, et al. Activation of HDAC8 Can Suppress the Proliferation of Osteosarcoma Cells via and STAT3/ERK Signaling Pathways. Annals of clinical and laboratory science. 2023 Nov;53(6):920-930. [Content Brief]
[2]. Ha SD, et al. HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells. Toxins. 2017 May 16;9(5):162. [Content Brief]
[3]. Akhter S, et al. Synthesis, crystal structure and Hirshfeld Surface analysis of benzamide derivatives of thiourea as potent inhibitors of α-glucosidase in-vitro. Bioorganic chemistry. 2021 Feb;107:104531. [Content Brief]
[4]. Singh RK, et al. Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels. The Journal of biological chemistry. 2015 Mar 06;290(10):6607-19. [Content Brief]
[5]. Singh RK, et al. Histone deacetylase activators: N-acetylthioureas serve as highly potent and isozyme selective activators for human histone deacetylase-8 on a fluorescent substrate. Bioorganic & medicinal chemistry letters. 2011 Oct 01;21(19):5920-3. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9014 mL | 19.5069 mL | 39.0137 mL | 97.5343 mL |
| 5 mM | 0.7803 mL | 3.9014 mL | 7.8027 mL | 19.5069 mL | |
| 10 mM | 0.3901 mL | 1.9507 mL | 3.9014 mL | 9.7534 mL | |
| 15 mM | 0.2601 mL | 1.3005 mL | 2.6009 mL | 6.5023 mL | |
| 20 mM | 0.1951 mL | 0.9753 mL | 1.9507 mL | 4.8767 mL | |
| 25 mM | 0.1561 mL | 0.7803 mL | 1.5605 mL | 3.9014 mL | |
| 30 mM | 0.1300 mL | 0.6502 mL | 1.3005 mL | 3.2511 mL | |
| 40 mM | 0.0975 mL | 0.4877 mL | 0.9753 mL | 2.4384 mL | |
| 50 mM | 0.0780 mL | 0.3901 mL | 0.7803 mL | 1.9507 mL | |
| 60 mM | 0.0650 mL | 0.3251 mL | 0.6502 mL | 1.6256 mL | |
| 80 mM | 0.0488 mL | 0.2438 mL | 0.4877 mL | 1.2192 mL | |
| 100 mM | 0.0390 mL | 0.1951 mL | 0.3901 mL | 0.9753 mL |